Influence of Atenolol and Nifedipine on Nitric-Oxide Deficient Cardiomyocyte Hypertrophy and Expression of the Cardio-Endocrine Peptide Intermedin and its Receptor Components | Zendy

David Bell | Zendy; You You Zhao | Zendy; Adrian Devine | Zendy; Barbara J. McDermott | Zendy

Open Access

Influence of Atenolol and Nifedipine on Nitric-Oxide Deficient Cardiomyocyte Hypertrophy and Expression of the Cardio-Endocrine Peptide Intermedin and its Receptor Components

Author(s) -

David Bell,

You You Zhao,

Adrian Devine,

Barbara J. McDermott

Publication year - 2008

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000113870

Subject(s) - atenolol , endocrinology , medicine , adrenomedullin , nifedipine , muscle hypertrophy , blood pressure , receptor , chemistry , calcium

Chronic inhibition of nitric oxide (NO) synthesis is associated with hypertension, myocardial ischemia, oxidative stress and hypertrophy; expression of adrenomedullin (AM) and intermedin (IMD) and their receptor activity modifying proteins (RAMPs 1-3) is augmented in cardiomyocytes, indicating that the myocardial AM/ IMD system may be activated in response to pressure loading and ischemic insult. The aim was to examine effects on (i) parameters of cardiomyocyte hypertrophy and on (ii) expression of AM and IMD and their receptor components in NO-deficient cardiomyocytes of an intervention chosen specifically for ability to alleviate pressure loading and ischemic injury concurrently.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research